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Abstract 
Since the late 1970s, ecstasy (MDMA) has enjoyed increasing popularity as a recreational drug. We report a 
dramatic increase in reports of ecstasy ingestion to the National Poisons Information Centre from zero in 
January 1991 to thirty seven in June 1992. We have analysed these thirty seven cases retrospectively for age 
and sex distribution, clinical details and outcome. The patients involved were predominantly male (80%) 
and aged 10-30 years, the highest incidence being in the 16-25 year old age group. Thirty two (86%) 
patients were symptomatic. Symptoms in most cases were relatively mild. One death was reported due to 
congestive heart failure. The symptoms most frequently reported include dilated pupils, agitation, 
excitement, hallucinations, tachycardia, palpitations, CNS depression, incontinence and psychiatric 
symptoms. 
Introduction 
Ecstasy (MDMA, 3,4-methylenedioxymetamphetamine) is a semi-synthetic amphetamine derivative which 
was developed as an appetite suppressant in 1914, but was never marketed as such. In the early 1970s it was 
used in psychotherapy to facilitate therapeutic communication and to improve patient self-esteem.1,2 Since 
the late 1970s ecstasy (also known as “XTC”, “Adam”, “MDM” and “M and M”) has enjoyed increasing 
popularity as a recreational drug. In July 1985 MDMA was classed as a Schedule 1 drug with “high 
potential for abuse and without accepted medical use”. 
 The effects of MDMA are usually euphorigenic. It produces a heightened sense of self-awareness, 
enhanced sociability, benevolence and sustained energy. Ecstasy is often taken in Britain3 and Ireland as a 
“dance drug” at “rave” parties where its use is associated with extreme physical activity which may 
compound the toxic effects of the drug. In Britain at least seven deaths have followed use of ecstasy as a 
“dance drug”.3 The increasing number of calls we are receiving at the Poisons Information Centre about 
ecstasy ingestion prompted us to review the cases which have been reported to date. 
Methods 
This study retrospectively analysed all reports of ecstasy ingestion to the Poisons Information Centre 
between January 1991 and June 1992. We recorded patient age, sex and clinical details at the time of each 
call. We obtained the outcome of serious cases from the hospitals involved and the coroners report for any 
fatalities. 
Results 
Incidence – Ecstasy abuse has become more popular in Ireland within the past 18 months. Reports of 
ecstasy ingestion to the Poisons Information Centre have increased dramatically from zero in January 1991 
to 37 in June 1992 (Fig. 1). 
Age and sex distribution – The patients involved were predominantly male (80%) and spanned a range of 
ages from 10-30 years. The highest incidence was seen in the 16-25 year old age group (Fig.2). 
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Clinical details – In this study most patients had only mild symptoms following ecstasy ingestion. A wide 
variety of symptoms (summarised in Table 1) were reported. Eight patients had no symptoms, 18 patients 
reported only one symptom and 11 patients had two or more symptoms. The most common complaints were 
agitation, excitement, hallucinations, palpitations and psychiatric symptoms. The most common findings 
were dilated pupils, tachycardia, hypertension, CNS depression and incontinence, One fatality was reported 
during the study period. This occurred in a 17 year old male and was attributed to congestive heart failure. 
Since completion of the study one further fatality has been reported to the Poisons Information Centre. This 
occurred in a 19 year old male. 
Table 1 – Signs/symptoms reported following ecstasy ingestion 
Sign/symptom No of cases % of cases 
Agitation 9 24 
Hallucinations 5 13.5 
Excitement 4 13.5 
Psychiatric symptoms 3 8.1 
Palpitations 2 5.4 
Dilated pupils 2 5.4 
Hypertension 2 5.4 
Incontinence 2 5.4 
Tachycardia 2 5.4 
Coma 2 5.4 
Aggression 1 2.7 
Vomiting 1 2.7 
Trismus 1 2.7 
Hypokalaemia 1 2.7 
Muscle spasm 1 2.7 
Slurred speech 1 2.7 
Drowsiness 1 2.7 
Convulsions 1 2.7 
Depression 1 2.7 
Cardiorespiratory arrest 1 2.7 
Death 1 2.7 
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Discussion 
The exact mechanism of MDMA toxicity remains unclear. Its structural similarity to endogenous 
catecholamines results in stimulation of both sympathetic and central nervous systems.4 Animal 
experiments suggest it can cause long-term depletion of serotonin in the CNS.5 In overdose, MDMA acts as 
a sympathomimetic agent, stimulating both alpha- and beta adrenergic receptors6, leading to a sympathetic 
overdrive. Deaths which occur soon (<24 hrs post ingestion) are usually due to cardiac arrhythmias, seizures 
and CNS depression. Late deaths (24-48 hrs post ingestion) seem to result from a syndrome resembling 
mallignant hyperthermia.3 
It appears that MDMA may have cardiovascular actions similar to its parent amphetamines including 
increased cardiac output, hypertension and induction of arrythmias. Dowling7 studied a series of five deaths 
following ingestion of MDMA or MDEA (MDMA’s legal replacement, ‘Eve’). He attributed the death of a 
previously healthy eighteen year old to ventricular fibrillation following MDMA ingestion. The death 
reported during the study period was attributed to congestive heart failure in a previously healthy seventeen 
year old male. These may be examples of idiosyncratic reactions or may suggest a low toxic/therapeutic 
ratio for MDMA. It is also proposed that MDMA may induce or augment potentially fatal arrhythmias in 
individuals with predisposing cardiac disease.7 
 
 Hyperthermia is a frequent complication of ecstasy ingestion, particularly in fatal overdoses. Henry 
and co-workers8 suggested hyperthermia seen in MDMA overdose represents a failure of thermoregulation 
due to interaction of at least three factors: a central effect of the drug (which may be serotonergic), marked 
physical activity and inadequate fluid replacement. Reviewing seven fatalities following ecstasy ingestion in 
England, they described a clear pattern of toxicity characterised by hyperthermia, DIC, rhabdomyolysis and 
acute renal failure. The ecstasy-induced death of a nineteen year old male reported to the Poisons Centre 
since the completion of this study followed exactly this profile of toxicity (i.e. hyperthermia, DIC and 
complete renal failure). 
 Further possible complications of acute overdose include intracerebral haemorrhage (secondary to a 
sudden increase in blood pressure), muscle rigidity with rhabdomyolysis, disseminated intravascular 
coagulopathy, adult respiratory distress syndrome, acute renal failure, hepatocellular necrosis and coma.6,9 
 Chronic abuse of ecstasy has recently been reported to cause a number of dysphoric reactions 
including flashbacks10, anxiety, confusion, insomnia1, a paranoid psychosis clinically indistinguishable from 
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schizophrenia11, panic attacks12, recurrent jaundice13 and acute hepatitis.7,14 Most of these effects are 
thought to be reversible after a prolonged drug-free state. 
Treatment of ecstasy overdose – Since amphetamine overdose can affect multiple systems medical 
assessment should include monitoring of haemodynamic parameters, renal and clotting function, rectal 
temperature, psychological and neurological status. Management should be active and immediate. In 
patients who present within four hours of ingestion, gastric lavage should be followed by administration of 
activated charcoal. Further therapy depends on which symptoms predominate. 
 Anxiety, agitation and hyperactivity should generally be controlled by the use of repeated small 
doses of intravenous diazepam. Chlorpromazine has been suggested for treatment of severe agitation not 
controlled by diazepam, but it produces undesirable side effects and has been shown to enhance toxicity of 
some amphetamines.15,16,17 Haloperidol was proposed to be safer and more effective than chlorpromazine18 
and has been used successfully in MDMA overdose.19 However, due to their potential for enhanced toxicity, 
we do not recommend use of either of these two agents. Seizures should be treated with airway 
management, ventilatory support and intravenous diazepam. Convulsions refractory to diazepam may be 
controlled with phenytoin. 
 Tachycardia and hypertension should be treated with beta blockers (eg.atenolol) and alpha-blockers 
(eg. Phentolamine) respectively. Labetalol, a combined alpha- and beta-blocker, may be even more suitable. 
 Vigorous fluid replacement is necessary to correct volume depletion and to facilitate 
thermoregulation by sweating.20 Mild fever should be treated with cool compresses and sponging. Rectal 
temperatures exceeding 39°C should be treated more aggressively with hypothermic blankets and ice baths 
as well as administration of dantrolene. Dantrolene infusions were shown to rapidly correct hyperpyrexia 
and the hpermetabolic state seen in MDMA overdose.21 If dantrolene is ineffective in controlling pyrexia, 
the patient should be paralysed and mechanically ventilated. 
 Since amphetamines are weak bases urinary acidification increases the excretion of unmetabolised 
drug and causes a decrease in plasma half-life. The efficacy of this on clinical outcome, however, remains 
controversial since urinary acidification is contra-indicated in the presence of rhabdomyolysis and 
myoglobinaemia.22 This is due to the potential for renal failure from myoglobin precipitation in the tubules. 
Maintaining a high urine output will help prevent acute renal failure secondary to the myogloinaemia 
produced by rhabdomyolysis.22 
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